Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-25
DOI
10.1038/s41598-021-90451-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability
- (2019) Ena Ladi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular Approaches to Treating Pediatric Leukemias
- (2019) Michaela Kuhlen et al. Frontiers in Pediatrics
- Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence
- (2018) Mara Gavazzoni et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)
- (2018) Henry W. B. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma
- (2017) Gilbert J Rahme et al. NEURO-ONCOLOGY
- Proteasome inhibitor-induced gastrointestinal toxicity
- (2017) Romany L. Stansborough et al. Current Opinion in Supportive and Palliative Care
- MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
- (2017) Amanda C. Winters et al. Frontiers in Pediatrics
- Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
- (2017) Kazuya Takahashi et al. PLoS One
- Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
- (2016) Rimda Wanchoo et al. Clinical Journal of the American Society of Nephrology
- Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
- (2016) Denise Niewerth et al. Journal of Hematology & Oncology
- A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program
- (2016) L Jones et al. LEUKEMIA
- A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
- (2015) Gerjan de Bruin et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The novel 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
- (2015) M. Kraus et al. HAEMATOLOGICA
- A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia
- (2015) Lukas D. Wartman et al. LEUKEMIA & LYMPHOMA
- The novel 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
- (2015) M. Kraus et al. HAEMATOLOGICA
- Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4
- (2014) Han Liu et al. CANCER CELL
- Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97
- (2014) Zhe Sha et al. CURRENT BIOLOGY
- Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
- (2014) Gerjan de Bruin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bortezomib treatment causes long-term testicular dysfunction in young male mice
- (2014) Mi Hou et al. Molecular Cancer
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites
- (2013) Paul P. Geurink et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib
- (2013) Tamer B. Shabaneh et al. PLoS One
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
- (2012) Y. H. Messinger et al. BLOOD
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- Bortezomib Is Cytotoxic to the Human Growth Plate and Permanently Impairs Bone Growth in Young Mice
- (2012) Emma Eriksson et al. PLoS One
- Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
- (2011) Anne C. Mirabella et al. CHEMISTRY & BIOLOGY
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Mice completely lacking immunoproteasomes show major changes in antigen presentation
- (2011) Eleanor Z Kincaid et al. NATURE IMMUNOLOGY
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
- (2010) Ajita V. Singh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Proteome of platelets in patients with coronary artery disease
- (2010) Cristina Banfi et al. EXPERIMENTAL HEMATOLOGY
- Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
- (2010) M. Basler et al. JOURNAL OF IMMUNOLOGY
- Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells
- (2010) Senthil K. Radhakrishnan et al. MOLECULAR CELL
- Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-Dependent Feedback Loop
- (2010) Janos Steffen et al. MOLECULAR CELL
- A panel of subunit-selective activity-based proteasome probes
- (2010) Martijn Verdoes et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules
- (2010) B. Guillaume et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
- (2009) Matthew Britton et al. CHEMISTRY & BIOLOGY
- A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
- (2009) Tony Muchamuel et al. NATURE MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started